Skip to main content

Published locations for Pediatric AML: Gemtuzumab ozogamicin prior to allo-HCT increases risk for veno-occlusive disease

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Pediatric AML: Gemtuzumab ozogamicin prior to allo-HCT increases risk for veno-occlusive disease

User login

  • Reset your password
  • /content/pediatric-aml-gemtuzumab-ozogamicin-prior-allo-hct-increases-risk-veno-occlusive-disease
  • /hematology-oncology/article/239799/aml/pediatric-aml-gemtuzumab-ozogamicin-prior-allo-hct-increases